---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-008901"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:22:27.697967+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DSMB recommends CNS Pharma's Berubicin trial continue unmodified after interim analysis

## Summary
- DSMB recommended continuation of Berubicin vs. Lomustine Phase 2/3 trial in recurrent GBM based on comparable overall survival.
- Enrollment expected to complete early Q1 2024; primary endpoint is overall survival.
- CEO John Climaco stated recommendation reflects acceptable efficacy and safety as defined in protocol.
- FDA has granted Fast Track and Orphan Drug Designation for Berubicin for malignant glioma.

## SEC filing metadata
- accession: 0001683168-23-008901
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823008901/0001683168-23-008901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823008901/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-008901
- JSON: https://secwatch.observer/filing/0001683168-23-008901.json
- Plain text: https://secwatch.observer/filing/0001683168-23-008901.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.